Health Care [ 4/12 ] | Pharmaceuticals [ 26/74 ]
NASDAQ | Common Stock
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 20, 25 | 1.77 Increased by +115.85% | 1.54 Increased by +15.12% |
| Nov 7, 24 | 1.61 Increased by +203.77% | 1.59 Increased by +1.26% |
| Aug 8, 24 | 1.62 Increased by +376.47% | 1.49 Increased by +8.72% |
| May 9, 24 | 1.45 Increased by +384.31% | 0.73 Increased by +98.63% |
| Feb 22, 24 | 0.82 Increased by +490.48% | 0.66 Increased by +24.24% |
| Nov 7, 23 | 0.53 Increased by +5.20 K% | 0.52 Increased by +1.92% |
| Aug 3, 23 | 0.34 Increased by +6.25% | 0.29 Increased by +17.24% |
| May 4, 23 | -0.51 Decreased by -215.91% | 0.31 Decreased by -264.52% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 181.95 M Increased by +21.51% | 12.54 M Decreased by -60.75% | Increased by +6.89% Decreased by -67.70% |
| Sep 30, 24 | 159.30 M Increased by +16.53% | 9.34 M Decreased by -54.76% | Increased by +5.86% Decreased by -61.18% |
| Jun 30, 24 | 145.28 M Increased by +7.18% | 19.61 M Increased by +50.73% | Increased by +13.50% Increased by +40.64% |
| Mar 31, 24 | 144.92 M Increased by +0.11% | 27.71 M Increased by +259.03% | Increased by +19.12% Increased by +258.86% |
| Dec 31, 23 | 149.75 M Increased by +15.53% | 31.94 M Increased by +543.67% | Increased by +21.33% Increased by +484.05% |
| Sep 30, 23 | 136.71 M Increased by +7.63% | 20.63 M Increased by +4.42 K% | Increased by +15.09% Increased by +4.09 K% |
| Jun 30, 23 | 135.55 M Increased by +9.71% | 13.01 M Increased by +350.57% | Increased by +9.60% Increased by +328.39% |
| Mar 31, 23 | 144.77 M Increased by +72.85% | -17.43 M Decreased by -33.34% | Decreased by -12.04% Increased by +22.86% |